Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost. 

Access to Exclusive Content. FREE for Registered Users Only. 

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2023/07/btm_logo.png" alt="" class="wp-image-67254" style="width:204px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/btm">Research News and Market Data on BTM</a>



June 13, 2025 8:00 AM EDT <a href="https://d1io3yog0oux5.cloudfront.net/_20271bbf7f1610a14b22efc0b5e9e632/bitcoindepot/news/2025-06-13_Bitcoin_Depot_Adds_to_Bitcoin_Treasury_Holdings_101.pdf" target="_blank" rel="noreferrer noopener">Download as PDF</a>



<h3 class="wp-block-heading">Company Now Holds Over 100 BTC as Part of Long-Term Growth Strategy</h3>



ATLANTA, June 13, 2025 (GLOBE NEWSWIRE) --&nbsp;<a href="https://www.globenewswire.com/Tracker?data=qKi7V4_CfrL7pll2Ma0mgh8nyJC0XvL2Uu7eLK1Rwzy6NAw1r7jXgWfXV_1tE_aG0l-1Yjv255Nrp3voLrhlKaITXxCohVFxhX9jq3kn6sQ=" rel="noreferrer noopener" target="_blank">Bitcoin Depot</a>&nbsp;(NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced it has purchased additional Bitcoin (BTC) as part of its treasury strategy first&nbsp;<a href="https://www.globenewswire.com/Tracker?data=0iE3XOCDYzPXuca26IDLHzy6-J6ifX-xO-fmq_aGR_8UrX-s5UuVSkGeEjLwDxJR54W1mQ7ohDPnxAJix5fGdX5nfLYTQ5i9_KvZmvDvkQi5xvNWjFObd4Os_KQ68dfea5zYASuetMWdarBqk-NWr61GZ5qxbQdmuF5_M5yo95feBJZathSL-wxyn7IrZEYfPOrc9qAMNUDdU0ia4GuViw==" rel="noreferrer noopener" target="_blank">initiated</a>&nbsp;in June 2024.



The move follows the Company’s earlier purchases of 51 and 11 BTC in&nbsp;<a href="https://www.globenewswire.com/Tracker?data=bcgMHedrfXE2iBvlQs7oBWHjWjY6GnWfBWYLJB-1XlTfL5akyeLAOmvZ3edmJIv0_XRYUfnVXGwzIcqtaz1q1d9uPWr8GQQgPO_WnUgci0BN0oyosb08-eyWMdR6JI0e18I6cUuVw4jICuYt5Do0K-vCjTW9uYIg7S2llMTaerbxuZVuex_JSZqa4USWQ8gchKVSb-6ERpdmd1qiVWzLPA==" rel="noreferrer noopener" target="_blank">February 2025.</a>&nbsp;With this latest addition, Bitcoin Depot now holds over 100 BTC in its treasury, further reinforcing its belief in Bitcoin’s long-term potential as both a strategic asset and a store of value.



“As the digital asset landscape continues to evolve during a period of strong industry momentum and innovation, we view Bitcoin as a foundational piece of our long-term growth strategy, and this purchase is a continuation of that conviction,” said Brandon Mintz, CEO and founder of Bitcoin Depot. “As we expand our treasury and our footprint, we remain committed to enabling access to Bitcoin and aligning with its future.”



This announcement comes as Bitcoin continues to experience significant momentum in 2025, marked by policy and regulatory clarity, growing institutional demand, increased adoption, and the recent all-time price high of over $111,000.



Bitcoin Depot’s latest BTC purchase also follows a wave of strong business&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Xw-TsTxqaJN8O_pI01oeC83c2N2PMDFPwXEZuyZJQ1hzY5v1xdWRca7Gwsu0BygckWh_ooagSmcLu4UAtJLXXo2IrM8zN3Ii4-VyKyfE5hHkJWiZfRlVOxi_wiuX2-37u2B218e8StiLhbnU34CC7YlxW2K35a152sH1pIAdiUIpdVBap92Ph9jb2ZVUy-a0ebPTiaIRok7afq_CjQ488w==" rel="noreferrer noopener" target="_blank">growth</a>&nbsp;for the Company, including the recent strategic&nbsp;<a href="https://www.globenewswire.com/Tracker?data=aGti4dbdtvbfU3ZgfDMnww0TVRp9IqNZAu8rx87a7tJaJe_zGUKGVsatne9LUMrSxu8Jsv9LCCWfww67YXY1JnOpZUEGTHH38Lg7mPOLO5NgDpS1gLAncR54jq6G7iMvARwpK5vJnVhGOwZsOdz1JFun4yUfY4R1kF0XvgJyaKsC1d3CVkGodl91iLgDzzvfT5hQKf9gFyUMrpwZUC9Mbv2pTMQBDhM537DnRALbnFI=" rel="noreferrer noopener" target="_blank">acquisition</a>&nbsp;of regional operator Pelicoin’s assets to further strengthen its market leadership. Today, Bitcoin Depot operates the largest Bitcoin ATM network in North America, with more than 8,500 locations and a growing international footprint.



The financial terms of the transaction were not disclosed. For more information, visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=B0sEXx919v20axDq0YpTPmf5KeBnnNQ8yXyUZ4Zb_bxX2fRrLE557bv3M2C0X7N7FrG5JO4xSfnjwcgXapievbvegCoXt8w4_LD8tCnYkDE=" rel="noreferrer noopener" target="_blank">www.bitcoindepot.com.</a>



About Bitcoin Depot&nbsp; Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America with over 8,500 kiosk locations as of June 2025. Learn more at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=B0sEXx919v20axDq0YpTPg2OgIZTZ80mjP5SGtM5npC_amTtAiEZYDjFc-U3MzNioSCPCgzfgYLBn2RsbsXeNWHAxjBEP8uRqdYNFIRXhEeFCnZkW-EkspxQa4tyLzy5fbZxQ7jie_29M9_v-gRw6W11nlg2femeaFu6GBDEg2nXuT_10-RSbLoJDSXO6-z06gwmIwu_wEkNrOil-RL5NOSabR615ihACnwoZgPGwIrWpk3wfiywys0TDSEF7Ms9hz6ftM4VaLaeEmZsCQqb9g==" rel="noreferrer noopener" target="_blank">www.bitcoindepot.com</a>.&nbsp;



Cautionary Note Regarding Forward-Looking Statements This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as "anticipate," "appears," "approximately," "believe," "continue," "could," "designed," "effect," "estimate," "evaluate," "expect," "forecast," "goal," "initiative," "intend," "may," "objective," "outlook," "plan," "potential," "priorities," "project," "pursue," "seek," "should," "target," "when," "will," "would," or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.



These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.



We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.



Contacts:&nbsp;



Investors &nbsp; Cody Slach Gateway Group, Inc. &nbsp; 949-574-3860 &nbsp; <a href="https://www.globenewswire.com/Tracker?data=X1q-t9ivzcLao6K41SrmLH-pHhlYAcbqhyxmdJn0si20QCHPzPYthzs14aEpsdGxSRLzodzsLoKJG94B7FLJohGyDlmr4o6jvk1WNGSZLBE=" rel="noreferrer noopener" target="_blank">BTM@gateway-grp.com</a>&nbsp;



Media &nbsp; Brenlyn Motlagh, Ryan Deloney &nbsp; Gateway Group, Inc.&nbsp; 949-574-3860 &nbsp; <a href="https://www.globenewswire.com/Tracker?data=X1q-t9ivzcLao6K41SrmLKMC72JAO3WWrJjYxa_LI8mgpveCaZ866IOHD4GFsB0g9zLZMAp5vQ1B4VEh3NrYq5Oq4-48L_YAVsIVEsjQWD8=" rel="noreferrer noopener" target="_blank">BTM@gateway-grp.com</a>&nbsp;



<figure class="wp-block-image"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/227cfe7f-1e77-4101-a4a9-b129490d3fce"><img src="https://ml.globenewswire.com/media/227cfe7f-1e77-4101-a4a9-b129490d3fce/small/bitcoin-depot-logo-jpg.jpg" alt="Primary Logo"/></a></figure>



Source: Bitcoin Depot Inc.



Released June 13, 2025

Research News and Market Data on BTM



June 13, 2025 8:00 AM EDT Download as PDF



Company Now Holds Over 100 BTC as Part of Long-Term Growth Strategy



ATLANTA, June 13, 2025 (GLOBE NEWSWIRE) &#8212;&nbsp;Bitcoin Depot&nbsp;(NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced it has purchased additional Bitcoin (BTC) as part of its treasury strategy first&nbsp;initiated&nbsp;in June 2024.



The move follows the Company’s earlier purchases of 51 and 11 BTC in&nbsp;February 2025.&nbsp;With this latest addition, Bitcoin Depot now holds over 100 BTC in its treasury, further reinforcing its belief in Bitcoin’s long-term potential as both a strategic asset and a store of value.



“As the digital asset landscape continues to evolve during a period of strong industry momentum and innovation, we view Bitcoin as a foundational piece of our long-term growth strategy, and this purchase is a continuation of that conviction,” said Brandon Mintz, CEO and founder of Bitcoin Depot. “As we expand our treasury and our footprint, we remain committed to enabling access to Bitcoin and aligning with its future.”



This announcement comes as Bitcoin continues to experience significant momentum in 2025, marked by policy and regulatory clarity, growing institutional demand, increased adoption, and the recent all-time price high of over $111,000.



Bitcoin Depot’s latest BTC purchase also follows a wave of strong business&nbsp;growth&nbsp;for the Company, including the recent strategic&nbsp;acquisition&nbsp;of regional operator Pelicoin’s assets to further strengthen its market leadership. Today, Bitcoin Depot operates the largest Bitcoin ATM network in North America, with more than 8,500 locations and a growing international footprint.



The financial terms of the transaction were not disclosed. For more information, visit&nbsp;www.bitcoindepot.com.



About Bitcoin Depot&nbsp;Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America with over 8,500 kiosk locations as of June 2025. Learn more at&nbsp;www.bitcoindepot.com.&nbsp;



Cautionary Note Regarding Forward-Looking StatementsThis press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as &#8220;anticipate,&#8221; &#8220;appears,&#8221; &#8220;approximately,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;effect,&#8221; &#8220;estimate,&#8221; &#8220;evaluate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;initiative,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;outlook,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;priorities,&#8221; &#8220;project,&#8221; &#8220;pursue,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;when,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.



These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.



We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.



Contacts:&nbsp;



Investors &nbsp;Cody SlachGateway Group, Inc. &nbsp;949-574-3860 &nbsp;BTM@gateway-grp.com&nbsp;



Media &nbsp;Brenlyn Motlagh, Ryan Deloney &nbsp;Gateway Group, Inc.&nbsp;949-574-3860 &nbsp;BTM@gateway-grp.com&nbsp;







Source: Bitcoin Depot Inc.



Released June 13, 2025

Release - Bitcoin Depot Adds to Bitcoin Treasury Holdings Amid Continued Market Momentum

Bitcoin

Bitcoin Depot Inc.

Crypto

Kiosk

<figure class="wp-block-image aligncenter size-full"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/auiaf-logo-pr.png" alt="" class="wp-image-50091"/></figure>



<a href="http://www.channelchek.com/company/auiaf">Research News and Market Data on AUIAF </a>



<h3 class="wp-block-heading">June 13, 2025 7:35 AM EDT | Source:&nbsp;<a href="https://www.newsfilecorp.com/company/2477/Aurania-Resources-Ltd.">Aurania Resources Ltd.</a></h3>



Toronto, Ontario--(Newsfile Corp. - June 13, 2025) -&nbsp;Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) ("Aurania" or the "Company")&nbsp;announces that its shareholders approved all resolutions at the Company's Annual and Special Meeting of Shareholders (the "Meeting") which was held on Thursday, June 12, 2025. The formal part of the Meeting was followed by an update from Aurania's President &amp; CEO, Dr. Keith Barron. To access the replay of Dr. Barron's update on YouTube, click this link:&nbsp;<a href="https://api.newsfilecorp.com/redirect/QOeLrTByWX">https://youtu.be/m0SIk501QtY</a>



At the Meeting, shareholders approved the financial statements for the year-ended December 31, 2024, and the report of the auditors thereon, the appointment of auditors, election of directors, and the Company's incentive stock option plan for the upcoming year. Details of these matters are disclosed in the Management Information Circular for the Meeting dated April 30, 2025, and posted under the Company's profile on&nbsp;<a href="https://api.newsfilecorp.com/redirect/m3rDoUmErp">www.sedarplus.ca</a>&nbsp;and on the Company's corporate website&nbsp;<a href="https://api.newsfilecorp.com/redirect/kObNzT8woy">http://www.aurania.com/investors/annual-general-meeting/</a>.



Clarification to Press Release Dated June 11, 2025



Further to the Company's&nbsp;<a href="https://api.newsfilecorp.com/redirect/BprXNhrWyJ">press release dated June 11, 2025</a>, the Company wishes to clarify the terms of the proposed fee that the Company would be required to pay as presented by ARCOM. As currently contemplated, half of this fee is expected to be due by July 31, 2025, and the remaining 50% is expected to be due by January 31, 2026.



About Aurania



Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities - Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.



Information on Aurania and technical reports are available at&nbsp;<a href="https://api.newsfilecorp.com/redirect/55wEpseGZZ">www.aurania.com</a>&nbsp;and&nbsp;<a href="https://api.newsfilecorp.com/redirect/LGYQ7hw5Pa">www.sedarplus.ca</a>, as well as on Facebook at&nbsp;<a href="https://api.newsfilecorp.com/redirect/oLjVJcDp47">https://www.facebook.com/auranialtd/</a>, Twitter at&nbsp;<a href="https://api.newsfilecorp.com/redirect/O3KBLUDn4D">https://twitter.com/auranialtd</a>, and LinkedIn at&nbsp;<a href="https://api.newsfilecorp.com/redirect/PLx5McAjVK">https://www.linkedin.com/company/aurania-resources-ltd-</a>.



For further information, please contact:



Carolyn Muir VP Corporate Development &amp; Investor Relations Aurania Resources Ltd. (416) 367-3200 <a href="mailto:carolyn.muir@aurania.com">carolyn.muir@aurania.com</a>



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



<figure class="wp-block-image"><img src="https://api.newsfilecorp.com/newsinfo/255465/157/aHR0cHM6Ly91cmwuZW1haWxwcm90ZWN0aW9uLmxpbmsv" alt="info"/></figure>



SOURCE:&nbsp;<a href="https://www.newsfilecorp.com/company/2477/Aurania-Resources-Ltd.">Aurania Resources Ltd.</a>

Research News and Market Data on AUIAF 



June 13, 2025 7:35 AM EDT | Source:&nbsp;Aurania Resources Ltd.



Toronto, Ontario&#8211;(Newsfile Corp. &#8211; June 13, 2025) &#8211;&nbsp;Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (&#8220;Aurania&#8221; or the &#8220;Company&#8221;)&nbsp;announces that its shareholders approved all resolutions at the Company&#8217;s Annual and Special Meeting of Shareholders (the &#8220;Meeting&#8221;) which was held on Thursday, June 12, 2025. The formal part of the Meeting was followed by an update from Aurania&#8217;s President &amp; CEO, Dr. Keith Barron. To access the replay of Dr. Barron&#8217;s update on YouTube, click this link:&nbsp;https://youtu.be/m0SIk501QtY



At the Meeting, shareholders approved the financial statements for the year-ended December 31, 2024, and the report of the auditors thereon, the appointment of auditors, election of directors, and the Company&#8217;s incentive stock option plan for the upcoming year. Details of these matters are disclosed in the Management Information Circular for the Meeting dated April 30, 2025, and posted under the Company&#8217;s profile on&nbsp;www.sedarplus.ca&nbsp;and on the Company&#8217;s corporate website&nbsp;http://www.aurania.com/investors/annual-general-meeting/.



Clarification to Press Release Dated June 11, 2025



Further to the Company&#8217;s&nbsp;press release dated June 11, 2025, the Company wishes to clarify the terms of the proposed fee that the Company would be required to pay as presented by ARCOM. As currently contemplated, half of this fee is expected to be due by July 31, 2025, and the remaining 50% is expected to be due by January 31, 2026.



About Aurania



Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities &#8211; Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.



Information on Aurania and technical reports are available at&nbsp;www.aurania.com&nbsp;and&nbsp;www.sedarplus.ca, as well as on Facebook at&nbsp;https://www.facebook.com/auranialtd/, Twitter at&nbsp;https://twitter.com/auranialtd, and LinkedIn at&nbsp;https://www.linkedin.com/company/aurania-resources-ltd-.



For further information, please contact:



Carolyn MuirVP Corporate Development &amp; Investor RelationsAurania Resources Ltd.(416) 367-3200carolyn.muir@aurania.com



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.







SOURCE:&nbsp;Aurania Resources Ltd.

Release - Aurania Shareholders Approve All Resolutions at Annual Meeting

AUIAF

Aurania Resources Ltd.

Natural Resouces

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/tnxp_logo.png" alt="" class="wp-image-49291" style="width:166px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/tnxp">Research News and Market Data on TNXP</a>



June 13, 2025 7:00am EDT <a href="https://d1io3yog0oux5.cloudfront.net/_9b638f166064e21dbafa05a321ea8393/tonixpharma/news/2025-06-13_Tonix_Pharmaceuticals_Announces_Appointment_of_1576.pdf" target="_blank" rel="noreferrer noopener">Download as PDF</a>



Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis



Led launch of Tonix Medicines, acquisition of migraine assets Zembrace®&nbsp;SymTouch®&nbsp;and Tosymra®, and recruitment of commercial leadership team



Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year



CHATHAM, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the appointment of James “Jim” Hunter to its Board of Directors, effective June 12, 2025. Mr. Hunter most recently served as Executive Vice President, Commercial at Tonix, where he was responsible for building the Company’s commercial subsidiary, Tonix Medicines, and successfully executing its entry into the migraine market.



“Jim’s appointment to our Board comes at a pivotal moment as we continue to expand our commercial footprint and intensify our pre-commercial efforts for the potential launch of TNX-102 SL for fibromyalgia later this year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Having successfully built Tonix Medicines from the ground up, Jim brings a unique operational perspective and deep commercial expertise that will be invaluable as we advance our commercial strategy and long-term growth.”



In his role as Executive Vice President of Commercial Operations at Tonix Pharmaceuticals and President of Tonix Medicines from June 2023 to December 2024, Mr. Hunter was responsible for managing all aspects of Tonix’s commercial efforts, including sales, marketing, market access and other operational and strategic initiatives. In addition to its ongoing commercial activities with respect Tosymra and Zembrace, Tonix Medicines is actively involved in TNX-SL 102 pre-launch activities including launch strategy, market analysis, product positioning, and market access initiatives.



Previously, Mr. Hunter was CEO and Co-founder of Validus Pharmaceuticals from 2007 to 2018, where he was responsible for more than two dozen successful product acquisitions from companies such as Shire, Roche, Novartis and Sanofi. Jim was also Co-Founder of Relialab, a diagnostics company focused on CLIA-waived, point-of-care psychiatric testing. Prior to these ventures, Mr. Hunter was Executive Director of Neuroscience Sales at Novartis Pharmaceuticals, where he launched and supported products in schizophrenia, epilepsy, migraine, Parkinson’s and Alzheimer’s. Mr. Hunter also served as Executive Director of the Northeast Business Unit at Ciba Geigy Pharmaceuticals, where he was responsible for the General Practice and hospital sales force and Regional Managed Care. Mr. Hunter received his B.S. at Seton Hall University and earned his M.B.A at Fairleigh Dickinson University.



“I’m honored to join Tonix’s Board at such an exciting juncture,” said Mr. Hunter. “It’s been a privilege to help build Tonix Medicines and launch the Company’s commercial capabilities. I look forward to continuing to support Tonix’s mission as a member of the Board and contributing to its next phase of growth.”



“I’m grateful to Jim for creating and building our commercial department which has positioned us well to launch TNX-102 SL for the management of fibromyalgia,” said Thomas Englese, EVP of Commercial Operations and leader of Tonix Medicines. “Jim’s continued strategic involvement as we prepare for the launch and continue to build our commercial infrastructure will be incredibly valuable.”



Tonix Pharmaceuticals Holding Corp.*



Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace®&nbsp;SymTouch®&nbsp;(sumatriptan injection) 3 mg and Tosymra®&nbsp;(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.



* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.



Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.



This press release and further information about Tonix can be found at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=kb5wAwKsx48EqrJAfYKT3RjzAv8bSGTpMe4M9kaJfW8Tl8eGCyk-jYSTU13kZqpImPIVQ0qNCuVfkx6SLeBpW-taheZZrUq-MtM4chPNG6k=" rel="noreferrer noopener" target="_blank">www.tonixpharma.com</a>.



Forward Looking Statements



Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.



Investor Contact



Jessica Morris Tonix Pharmaceuticals <a href="https://www.globenewswire.com/Tracker?data=Y1xcY_NrqxM3e-825tnCxzLkXJSOMPhq_XNBHb-DKuR4fWjBpqXQj_tHZhvrW13U9Q1Tm9UPdQYBZBidufvlpGGa0dWUQpnhYrRwbXEH23eedElKjIN0KhClHR9RJeOUqfAIV8UxsaIdgmJ0f1XrFw==" rel="noreferrer noopener" target="_blank">investor.relations@tonixpharma.com</a> (862) 799-8599



Peter Vozzo ICR Healthcare <a href="https://www.globenewswire.com/Tracker?data=Wzp8ag16QxiacNcIOOlTe1oDv1P9qHRJ-o2b-WmyBvtlphKMj1Z73ofHMNSDM0CXYM82mJ7rl0d0sJPLqb4M3DDXovOWrwCIwO-dyOMyY3Vq3BLyqxTmJ8hGFCoKapjQ" rel="noreferrer noopener" target="_blank">peter.vozzo@icrhealthcare.com</a> (443) 213-0505



Media Contact



Ray Jordan Putnam Insights <a href="https://www.globenewswire.com/Tracker?data=-fGg-8yXv3Q_kuYGZwMHydMFritEFFIjQ6Pxhl5Ncnb6D5q22iwjEBmGWFt9tbP5iDEYPtoga3EbeL7TyHHrOzBozVqZ3bir0cGuT0YHMo0=" rel="noreferrer noopener" target="_blank">ray@putnaminsights.com</a><a href="https://www.globenewswire.com/Tracker?data=QBZRRa8se8zK7jS2BjjuKMddGqrYo1rWaTvw25DrjTBVtzaqGM0lmS5LzgLLctOf9CzXJMZiQZDWaPBN0-c33g==" rel="noreferrer noopener" target="_blank"> </a>(949) 245-5432



Indication and Usage



Zembrace®&nbsp;SymTouch®&nbsp;(sumatriptan succinate) injection (Zembrace) and Tosymra®&nbsp;(sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.



Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.



Important Safety Information



Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:



<ul class="wp-block-list">
<li>discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back</li>



<li>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</li>



<li>pain or discomfort in your arms, back, neck, jaw or stomach</li>



<li>shortness of breath with or without chest discomfort</li>



<li>breaking out in a cold sweat</li>



<li>nausea or vomiting</li>



<li>feeling lightheaded</li>
</ul>



Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.



Do not use Zembrace or Tosymra if you have:



<ul class="wp-block-list">
<li>history of heart problems</li>



<li>narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</li>



<li>uncontrolled high blood pressure</li>



<li>hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.</li>



<li>had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</li>



<li>severe liver problems</li>



<li>taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.</li>



<li>are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</li>



<li>an allergy to sumatriptan or any of the components of Zembrace or Tosymra</li>
</ul>



Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.



Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



Zembrace and Tosymra may cause serious side effects including:



<ul class="wp-block-list">
<li>changes in color or sensation in your fingers and toes</li>



<li>sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever</li>



<li>cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet</li>



<li>increased blood pressure including a sudden severe increase even if you have no history of high blood pressure</li>



<li>medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.</li>



<li>serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.</li>



<li>hives (itchy bumps); swelling of your tongue, mouth, or throat</li>



<li>seizures even in people who have never had seizures before</li>
</ul>



The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).



Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.



This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.



You are encouraged to report adverse effects of prescription drugs to the FDA. Visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=9hiGap8tZe12-faSYDWY03Wqy8QAwTYfn2HKeAPGl0MjQpnlwV2421tZZm5T9yNa6O3NqCpktjcmOdxQwW6xZ6L4Db3h7KOvbIa32NA4fY0=" rel="noreferrer noopener" target="_blank">www.fda.gov/medwatch</a>, or call 1-800-FDA-1088.



<figure class="wp-block-image"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/16aad249-3d33-4501-b3d9-118a703fa46e"><img src="https://ml.globenewswire.com/media/16aad249-3d33-4501-b3d9-118a703fa46e/small/tonix2-jpg.jpg" alt="Primary Logo"/></a></figure>



Source: Tonix Pharmaceuticals Holding Corp.



Released June 13, 2025

Research News and Market Data on TNXP



June 13, 2025 7:00am EDT Download as PDF



Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis



Led launch of Tonix Medicines, acquisition of migraine assets Zembrace®&nbsp;SymTouch®&nbsp;and Tosymra®, and recruitment of commercial leadership team



Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year



CHATHAM, N.J., June 13, 2025 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the appointment of James “Jim” Hunter to its Board of Directors, effective June 12, 2025. Mr. Hunter most recently served as Executive Vice President, Commercial at Tonix, where he was responsible for building the Company’s commercial subsidiary, Tonix Medicines, and successfully executing its entry into the migraine market.



“Jim’s appointment to our Board comes at a pivotal moment as we continue to expand our commercial footprint and intensify our pre-commercial efforts for the potential launch of TNX-102 SL for fibromyalgia later this year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Having successfully built Tonix Medicines from the ground up, Jim brings a unique operational perspective and deep commercial expertise that will be invaluable as we advance our commercial strategy and long-term growth.”



In his role as Executive Vice President of Commercial Operations at Tonix Pharmaceuticals and President of Tonix Medicines from June 2023 to December 2024, Mr. Hunter was responsible for managing all aspects of Tonix’s commercial efforts, including sales, marketing, market access and other operational and strategic initiatives. In addition to its ongoing commercial activities with respect Tosymra and Zembrace, Tonix Medicines is actively involved in TNX-SL 102 pre-launch activities including launch strategy, market analysis, product positioning, and market access initiatives.



Previously, Mr. Hunter was CEO and Co-founder of Validus Pharmaceuticals from 2007 to 2018, where he was responsible for more than two dozen successful product acquisitions from companies such as Shire, Roche, Novartis and Sanofi. Jim was also Co-Founder of Relialab, a diagnostics company focused on CLIA-waived, point-of-care psychiatric testing. Prior to these ventures, Mr. Hunter was Executive Director of Neuroscience Sales at Novartis Pharmaceuticals, where he launched and supported products in schizophrenia, epilepsy, migraine, Parkinson’s and Alzheimer’s. Mr. Hunter also served as Executive Director of the Northeast Business Unit at Ciba Geigy Pharmaceuticals, where he was responsible for the General Practice and hospital sales force and Regional Managed Care. Mr. Hunter received his B.S. at Seton Hall University and earned his M.B.A at Fairleigh Dickinson University.



“I’m honored to join Tonix’s Board at such an exciting juncture,” said Mr. Hunter. “It’s been a privilege to help build Tonix Medicines and launch the Company’s commercial capabilities. I look forward to continuing to support Tonix’s mission as a member of the Board and contributing to its next phase of growth.”



“I’m grateful to Jim for creating and building our commercial department which has positioned us well to launch TNX-102 SL for the management of fibromyalgia,” said Thomas Englese, EVP of Commercial Operations and leader of Tonix Medicines. “Jim’s continued strategic involvement as we prepare for the launch and continue to build our commercial infrastructure will be incredibly valuable.”



Tonix Pharmaceuticals Holding Corp.*



Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace®&nbsp;SymTouch®&nbsp;(sumatriptan injection) 3 mg and Tosymra®&nbsp;(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.



* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.



Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.



This press release and further information about Tonix can be found at&nbsp;www.tonixpharma.com.



Forward Looking Statements



Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix&#8217;s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix&#8217;s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.



Investor Contact



Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 799-8599



Peter VozzoICR Healthcarepeter.vozzo@icrhealthcare.com(443) 213-0505



Media Contact



Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432



Indication and Usage



Zembrace®&nbsp;SymTouch®&nbsp;(sumatriptan succinate) injection (Zembrace) and Tosymra®&nbsp;(sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.



Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.



Important Safety Information



Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:




discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back



severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw



pain or discomfort in your arms, back, neck, jaw or stomach



shortness of breath with or without chest discomfort



breaking out in a cold sweat



nausea or vomiting



feeling lightheaded




Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.



Do not use Zembrace or Tosymra if you have:




history of heart problems



narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)



uncontrolled high blood pressure



hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.



had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation



severe liver problems



taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.



are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.



an allergy to sumatriptan or any of the components of Zembrace or Tosymra




Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.



Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



Zembrace and Tosymra may cause serious side effects including:




changes in color or sensation in your fingers and toes



sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever



cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet



increased blood pressure including a sudden severe increase even if you have no history of high blood pressure



medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.



serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.



hives (itchy bumps); swelling of your tongue, mouth, or throat



seizures even in people who have never had seizures before




The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).



Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.



This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.



You are encouraged to report adverse effects of prescription drugs to the FDA. Visit&nbsp;www.fda.gov/medwatch, or call 1-800-FDA-1088.







Source: Tonix Pharmaceuticals Holding Corp.



Released June 13, 2025

Release - Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Biopharmaceuticals

TNXP

Tonix Pharmaceuticals Holding Corp.

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Small-cap defense companies operate in specialized sectors with higher agility and acquisition potential compared to mega-cap contractors - Cybersecurity, drone systems, and advanced materials offer the strongest growth opportunities in current geopolitical climate - Market volatility creates entry opportunities before institutional recognition drives valuations higher</td></tr></tbody></table></figure>



While major defense contractors like Lockheed Martin and Northrop Grumman capture headlines during geopolitical tensions, astute small-cap investors should turn their attention to the lesser-known defense players positioned to benefit from increased military spending and technological innovation. Small-cap defense companies often operate in specialized niches that make them indispensable to larger prime contractors and government agencies, and unlike their mega-cap counterparts, these firms can pivot quickly to emerging threats and technologies, making them attractive acquisition targets or compelling long-term growth stories.



The current geopolitical climate, highlighted by recent Middle East tensions and ongoing global conflicts, has created a sustained tailwind for defense spending. President Trump's pledge of a $1 trillion defense budget, while potentially falling short in fiscal 2026, signals a multi-year commitment to military modernization that extends far beyond traditional weapons systems. This environment particularly benefits small-cap companies specializing in cybersecurity and electronic warfare, where firms focusing on cyber defense, electronic countermeasures, and signal intelligence are experiencing unprecedented demand. These companies often possess proprietary technologies that are difficult to replicate and command premium margins, creating substantial competitive advantages.



The drone revolution presents another compelling opportunity, extending beyond consumer applications into military reconnaissance, logistics, and combat operations. Small-cap manufacturers of specialized UAV components, software, and support systems are capturing market share from traditional aerospace giants, while companies developing next-generation materials for armor, stealth applications, and extreme environment operations often fly under the radar while generating substantial returns for early investors.



When evaluating small-cap defense opportunities, successful investors focus on companies with government contract diversification across multiple agencies and international allies to reduce single-customer risk. The most attractive investments typically feature proprietary technology through patents and specialized expertise that create competitive moats justifying premium valuations. Experienced management teams with deep defense industry connections and security clearances consistently accelerate contract wins, while financial discipline demonstrated through strong balance sheets and consistent cash flow generation proves crucial despite the lumpy nature of contract timing.



Small-cap defense investing requires careful risk assessment, as government budget cycles, security clearance requirements, and regulatory compliance create unique challenges. However, companies that successfully navigate these hurdles often enjoy sustained competitive advantages and multi-year revenue visibility that reward patient investors. The current environment of elevated geopolitical tensions, combined with technological disruption in warfare, creates an ideal backdrop for small-cap defense investments. While large-cap names grab immediate attention during crisis periods, the real long-term value creation often occurs in the innovative small companies that power the next generation of military capabilities. Smart investors should use market volatility as an opportunity to build positions in quality small-cap defense names before institutional recognition drives valuations higher.

Key Points: &#8211; Small-cap defense companies operate in specialized sectors with higher agility and acquisition potential compared to mega-cap contractors&#8211; Cybersecurity, drone systems, and advanced materials offer the strongest growth opportunities in current geopolitical climate&#8211; Market volatility creates entry opportunities before institutional recognition drives valuations higher



While major defense contractors like Lockheed Martin and Northrop Grumman capture headlines during geopolitical tensions, astute small-cap investors should turn their attention to the lesser-known defense players positioned to benefit from increased military spending and technological innovation. Small-cap defense companies often operate in specialized niches that make them indispensable to larger prime contractors and government agencies, and unlike their mega-cap counterparts, these firms can pivot quickly to emerging threats and technologies, making them attractive acquisition targets or compelling long-term growth stories.



The current geopolitical climate, highlighted by recent Middle East tensions and ongoing global conflicts, has created a sustained tailwind for defense spending. President Trump&#8217;s pledge of a $1 trillion defense budget, while potentially falling short in fiscal 2026, signals a multi-year commitment to military modernization that extends far beyond traditional weapons systems. This environment particularly benefits small-cap companies specializing in cybersecurity and electronic warfare, where firms focusing on cyber defense, electronic countermeasures, and signal intelligence are experiencing unprecedented demand. These companies often possess proprietary technologies that are difficult to replicate and command premium margins, creating substantial competitive advantages.



The drone revolution presents another compelling opportunity, extending beyond consumer applications into military reconnaissance, logistics, and combat operations. Small-cap manufacturers of specialized UAV components, software, and support systems are capturing market share from traditional aerospace giants, while companies developing next-generation materials for armor, stealth applications, and extreme environment operations often fly under the radar while generating substantial returns for early investors.



When evaluating small-cap defense opportunities, successful investors focus on companies with government contract diversification across multiple agencies and international allies to reduce single-customer risk. The most attractive investments typically feature proprietary technology through patents and specialized expertise that create competitive moats justifying premium valuations. Experienced management teams with deep defense industry connections and security clearances consistently accelerate contract wins, while financial discipline demonstrated through strong balance sheets and consistent cash flow generation proves crucial despite the lumpy nature of contract timing.



Small-cap defense investing requires careful risk assessment, as government budget cycles, security clearance requirements, and regulatory compliance create unique challenges. However, companies that successfully navigate these hurdles often enjoy sustained competitive advantages and multi-year revenue visibility that reward patient investors. The current environment of elevated geopolitical tensions, combined with technological disruption in warfare, creates an ideal backdrop for small-cap defense investments. While large-cap names grab immediate attention during crisis periods, the real long-term value creation often occurs in the innovative small companies that power the next generation of military capabilities. Smart investors should use market volatility as an opportunity to build positions in quality small-cap defense names before institutional recognition drives valuations higher.

Small-Cap Defense Stocks: Hidden Gems in Times of Global Uncertainty

Defense

Geopolitical Tensions

Global Conflict

Middle East

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Friday, June 13, 2025



Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Noble Virtual Conference.&nbsp;On June 4, the company presented at the Noble Virtual Conference to the investment community. The presentation conducted by&nbsp;Heidy Chow, CFO, and Peter Lin, Sr. Manager, FP&amp;A, highlighted the company's release roadmap, unique product offerings, and portfolio diversification. A replay of the presentation can be viewed&nbsp;<a href="https://www.channelchek.com/videos/snail-snal-noble-capital-markets-virtual-conference-replay">here</a>.



Favorable release roadmap.&nbsp;The company has a busy release roadmap for 2025, which includes a 10th-anniversary expansion pack for ARK: Survival Evolved, a new expansion pack for ARK: Survival Ascended, and the release of Bellwright on Xbox in Q4. Additionally, nine new gaming titles are slated for 2025, including Robots at Midnight, Honeycomb, and Echoes of Elysium, which could have breakout potential. Additionally, the company recently expanded into new entertainment categories to further expand its portfolio.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27557">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Friday, June 13, 2025



Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Noble Virtual Conference.&nbsp;On June 4, the company presented at the Noble Virtual Conference to the investment community. The presentation conducted by&nbsp;Heidy Chow, CFO, and Peter Lin, Sr. Manager, FP&amp;A, highlighted the company&#8217;s release roadmap, unique product offerings, and portfolio diversification. A replay of the presentation can be viewed&nbsp;here.



Favorable release roadmap.&nbsp;The company has a busy release roadmap for 2025, which includes a 10th-anniversary expansion pack for ARK: Survival Evolved, a new expansion pack for ARK: Survival Ascended, and the release of Bellwright on Xbox in Q4. Additionally, nine new gaming titles are slated for 2025, including Robots at Midnight, Honeycomb, and Echoes of Elysium, which could have breakout potential. Additionally, the company recently expanded into new entertainment categories to further expand its portfolio.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Snail (SNAL) - Noble Virtual Conference Highlights

Gaming

Media

Snail Games

SNAL

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Friday, June 13, 2025



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Updating estimates.&nbsp;While we are maintaining our 2025 rail car delivery estimate of 4,710, we have lowered our second quarter expectations to 850 from 950 and increased our third quarter estimate to 1,790 from 1,690. Our 2025 EBITDA and EPS estimates are unchanged at $45.9 million, and $0.47, respectively. However, our second and third quarter EPS estimates are $0.06 and $0.20, respectively, compared to our prior estimates of $0.07 and $0.19.



Flexible production schedule.&nbsp;With FreightCar's asset-based lending facility, the company has greater flexibility to manage its production schedule, given that it can borrow against inventory. The company has the ability to produce rail cars associated with firm orders and hold them for delivery to suit customer needs.&nbsp;



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27559">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Friday, June 13, 2025



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Updating estimates.&nbsp;While we are maintaining our 2025 rail car delivery estimate of 4,710, we have lowered our second quarter expectations to 850 from 950 and increased our third quarter estimate to 1,790 from 1,690. Our 2025 EBITDA and EPS estimates are unchanged at $45.9 million, and $0.47, respectively. However, our second and third quarter EPS estimates are $0.06 and $0.20, respectively, compared to our prior estimates of $0.07 and $0.19.



Flexible production schedule.&nbsp;With FreightCar&#8217;s asset-based lending facility, the company has greater flexibility to manage its production schedule, given that it can borrow against inventory. The company has the ability to produce rail cars associated with firm orders and hold them for delivery to suit customer needs.&nbsp;



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

FreightCar America (RAIL) - Modest Adjustments to Our 2025 Quarterly Estimates; No Change to Full Year Projections

FreightCar America

RAIL

Rail car

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Friday, June 13, 2025



Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Bolsters its southern operations. On June 11, the company announced that it had acquired the assets of Pelicoin, a crypto ATM company with operations in the Gulf South (particularly MS, AL, TX, TN). The additional kiosks, which we believe to be roughly 50, are expected to be fully integrated within several weeks. Industry consolidation. In our view, the acquisition demonstrates the attractive industry consolidation opportunity for the company. Notably, the Pelicoin acquisition marks the second time in the last 18 months that the company has opportunistically added to its kiosk fleet. In April 2024, the company acquired 2,300 kiosks at a 50% discount from a defunct operator. We believe, with its healthy cash balance of $35 million (as of 3/31/25), the company is well positioned to continue to consolidate the industry as opportunities arise.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27556">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Friday, June 13, 2025



Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Bolsters its southern operations. On June 11, the company announced that it had acquired the assets of Pelicoin, a crypto ATM company with operations in the Gulf South (particularly MS, AL, TX, TN). The additional kiosks, which we believe to be roughly 50, are expected to be fully integrated within several weeks.Industry consolidation. In our view, the acquisition demonstrates the attractive industry consolidation opportunity for the company. Notably, the Pelicoin acquisition marks the second time in the last 18 months that the company has opportunistically added to its kiosk fleet. In April 2024, the company acquired 2,300 kiosks at a 50% discount from a defunct operator. We believe, with its healthy cash balance of $35 million (as of 3/31/25), the company is well positioned to continue to consolidate the industry as opportunities arise.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Bitcoin Depot (BTM) - Pelicoin Pick-Up: A Nice Tuck-In Acquisition

Bitcoin ATM

Bitcoin Depot

Noble Capital Markets Research Morning Call

Stripe's acquisition of crypto wallet provider Privy represents far more than a simple technology purchase—it's a calculated move to position the payments giant at the forefront of the digital currency revolution. This strategic acquisition, coming on the heels of Stripe's massive $1.1 billion purchase of Bridge earlier this year, demonstrates the company's commitment to building a comprehensive cryptocurrency infrastructure that could fundamentally reshape how businesses and consumers interact with digital assets.



Privy's impressive scale provides immediate validation of the crypto wallet market's maturity. With over 75 million accounts across more than 1,000 developer teams facilitating billions in transactions, the New York-based startup has proven that cryptocurrency wallets can achieve mainstream adoption when properly executed. Founded in 2021 by Henri Stern and Asta Li, Privy solved a critical problem in the crypto ecosystem by creating developer-friendly APIs that eliminate the technical barriers traditionally associated with wallet creation and blockchain integration.



The timing of this acquisition is particularly significant given the broader cryptocurrency market's evolution toward practical utility rather than speculative trading. Privy's technology spans multiple high-growth sectors including decentralized finance, gaming, artificial intelligence agents, and consumer applications, indicating that crypto infrastructure is becoming integral to diverse business models rather than remaining confined to niche financial applications.



Stripe's strategic vision becomes clearer when considering how Privy's capabilities complement the company's existing strengths. The payments processor has built its reputation on simplifying complex financial operations for merchants, and cryptocurrency transactions represent the next logical frontier. By integrating Privy's wallet technology with Bridge's stablecoin infrastructure and Stripe's global payment network, the company is creating a unified platform that could make cryptocurrency transactions as seamless as traditional card payments.



The acquisition's structure reveals Stripe's confidence in Privy's independent value proposition. By allowing Privy to continue operating as an independent product, Stripe acknowledges that the crypto wallet market requires specialized expertise and dedicated focus. This approach mirrors successful technology acquisitions where the parent company provides resources and distribution while preserving the acquired company's innovative culture and technical capabilities.



Patrick Collison's statement about enabling "Internet-native financial services" hints at Stripe's larger ambition to challenge traditional banking infrastructure. The combination of wallet technology, stablecoin capabilities, and global payment processing creates a powerful alternative to conventional financial systems, particularly for international transactions where traditional banking remains slow and expensive.



The undisclosed acquisition price, while notable, is less important than the strategic implications. Privy's $40 million in raised capital from prominent investors including Ribbit Capital and Coinbase Ventures suggests a valuation multiple that reflects both current performance and future potential. For Stripe, which processes hundreds of billions in annual payment volume, the cost of this acquisition is minimal compared to the potential revenue from expanding into cryptocurrency infrastructure.



This acquisition positions Stripe to capture value from the inevitable growth in cryptocurrency adoption while maintaining its core business focus. As regulatory clarity improves and institutional adoption accelerates, companies with comprehensive crypto infrastructure will possess significant competitive advantages in the evolving digital economy.

Stripe&#8217;s acquisition of crypto wallet provider Privy represents far more than a simple technology purchase—it&#8217;s a calculated move to position the payments giant at the forefront of the digital currency revolution. This strategic acquisition, coming on the heels of Stripe&#8217;s massive $1.1 billion purchase of Bridge earlier this year, demonstrates the company&#8217;s commitment to building a comprehensive cryptocurrency infrastructure that could fundamentally reshape how businesses and consumers interact with digital assets.



Privy&#8217;s impressive scale provides immediate validation of the crypto wallet market&#8217;s maturity. With over 75 million accounts across more than 1,000 developer teams facilitating billions in transactions, the New York-based startup has proven that cryptocurrency wallets can achieve mainstream adoption when properly executed. Founded in 2021 by Henri Stern and Asta Li, Privy solved a critical problem in the crypto ecosystem by creating developer-friendly APIs that eliminate the technical barriers traditionally associated with wallet creation and blockchain integration.



The timing of this acquisition is particularly significant given the broader cryptocurrency market&#8217;s evolution toward practical utility rather than speculative trading. Privy&#8217;s technology spans multiple high-growth sectors including decentralized finance, gaming, artificial intelligence agents, and consumer applications, indicating that crypto infrastructure is becoming integral to diverse business models rather than remaining confined to niche financial applications.



Stripe&#8217;s strategic vision becomes clearer when considering how Privy&#8217;s capabilities complement the company&#8217;s existing strengths. The payments processor has built its reputation on simplifying complex financial operations for merchants, and cryptocurrency transactions represent the next logical frontier. By integrating Privy&#8217;s wallet technology with Bridge&#8217;s stablecoin infrastructure and Stripe&#8217;s global payment network, the company is creating a unified platform that could make cryptocurrency transactions as seamless as traditional card payments.



The acquisition&#8217;s structure reveals Stripe&#8217;s confidence in Privy&#8217;s independent value proposition. By allowing Privy to continue operating as an independent product, Stripe acknowledges that the crypto wallet market requires specialized expertise and dedicated focus. This approach mirrors successful technology acquisitions where the parent company provides resources and distribution while preserving the acquired company&#8217;s innovative culture and technical capabilities.



Patrick Collison&#8217;s statement about enabling &#8220;Internet-native financial services&#8221; hints at Stripe&#8217;s larger ambition to challenge traditional banking infrastructure. The combination of wallet technology, stablecoin capabilities, and global payment processing creates a powerful alternative to conventional financial systems, particularly for international transactions where traditional banking remains slow and expensive.



The undisclosed acquisition price, while notable, is less important than the strategic implications. Privy&#8217;s $40 million in raised capital from prominent investors including Ribbit Capital and Coinbase Ventures suggests a valuation multiple that reflects both current performance and future potential. For Stripe, which processes hundreds of billions in annual payment volume, the cost of this acquisition is minimal compared to the potential revenue from expanding into cryptocurrency infrastructure.



This acquisition positions Stripe to capture value from the inevitable growth in cryptocurrency adoption while maintaining its core business focus. As regulatory clarity improves and institutional adoption accelerates, companies with comprehensive crypto infrastructure will possess significant competitive advantages in the evolving digital economy.

Stripe's Crypto Wallet Acquisition: A Strategic Play for Digital Payment Dominance

Digital Currency

Privy

Stripe

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2023/08/cvkd_logo.png" alt="" class="wp-image-74250" style="width:120px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/cvkd">Research News and Market Data on CVKD</a>



<ul class="wp-block-list">
<li>LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke</li>



<li>Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event</li>



<li>Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population</li>
</ul>



PONTE VEDRA, Fla. –&nbsp;Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.



The research recently conducted by Guidehouse, an AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors, underscores the significant clinical and economic burden for LVAD patients who require chronic oral anticoagulation. Key findings include:



<ul class="wp-block-list">
<li>Major bleeds remain a primary cost driver, with average hospitalization costs (per event) of $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds.</li>
</ul>



Guidehouse’s analysis also identified tecarfarin – a novel, Phase 3-ready oral anticoagulant being developed by Cadrenal – as a potential alternative to warfarin to address the current unmet need in this patient population. Tecarfarin is designed to provide more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin. Its unique metabolism via a single enzyme (CES2) may reduce the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events.



“Despite decades of use, warfarin has significant limitations – especially in complex patients with LVADs,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “This research reinforces our conviction that tecarfarin has the potential to transform anticoagulation management for this high-risk population who currently has no alternative options.”



About Cadrenal Therapeutics, Inc.



<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cadrenal.com%2F&amp;esheet=54273071&amp;newsitemid=20250612613022&amp;lan=en-US&amp;anchor=Cadrenal+Therapeutics%2C+Inc.&amp;index=1&amp;md5=6cb02457640858a01bd47216cb60c665">Cadrenal Therapeutics, Inc.</a>&nbsp;is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options.



Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).



Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cadrenal.com%2F&amp;esheet=54273071&amp;newsitemid=20250612613022&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cadrenal.com%2F&amp;index=2&amp;md5=97137027c378bc050bf96187d2522dee">https://www.cadrenal.com/</a>and connect with us on&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcadrenal%2F&amp;esheet=54273071&amp;newsitemid=20250612613022&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=2ab538423463f40ed0c5fbd494182cea">LinkedIn</a>.



Safe Harbor



Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding Tecarfarin offering an alternative to warfarin for LVAD patients requiring chronic anticoagulation; providing more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin; Tecarfarin’s metabolism via a single enzyme (CES2) reducing the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events; transforming anticoagulation management for LVAD patients who currently have no alternative options; preventing heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation; addressing the unmet needs in anticoagulation therapy; reducing the clinical complexities of warfarin; and capturing value in a market with high demand for safer, more manageable treatment options. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for LVAD patients who require anticoagulation; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.



View source version on businesswire.com:&nbsp;<a href="https://www.businesswire.com/news/home/20250612613022/en/">https://www.businesswire.com/news/home/20250612613022/en/</a>



Corporate and Investor Relations Paul Sagan LaVoieHealthScience (617) 865-0041 <a href="mailto:psagan@lavoiehealthscience.com">psagan@lavoiehealthscience.com</a>



Media Andrew Korda LaVoieHealthScience (617) 865-0043 <a href="mailto:akorda@lavoiehealthscience.com">akorda@lavoiehealthscience.com</a>

Research News and Market Data on CVKD




LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke



Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event



Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population




PONTE VEDRA, Fla. –&nbsp;Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.



The research recently conducted by Guidehouse, an AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors, underscores the significant clinical and economic burden for LVAD patients who require chronic oral anticoagulation. Key findings include:




Major bleeds remain a primary cost driver, with average hospitalization costs (per event) of $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds.




Guidehouse’s analysis also identified tecarfarin – a novel, Phase 3-ready oral anticoagulant being developed by Cadrenal – as a potential alternative to warfarin to address the current unmet need in this patient population. Tecarfarin is designed to provide more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin. Its unique metabolism via a single enzyme (CES2) may reduce the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events.



“Despite decades of use, warfarin has significant limitations – especially in complex patients with LVADs,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “This research reinforces our conviction that tecarfarin has the potential to transform anticoagulation management for this high-risk population who currently has no alternative options.”



About Cadrenal Therapeutics, Inc.



Cadrenal Therapeutics, Inc.&nbsp;is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options.



Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).



Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit&nbsp;https://www.cadrenal.com/and connect with us on&nbsp;LinkedIn.



Safe Harbor



Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding Tecarfarin offering an alternative to warfarin for LVAD patients requiring chronic anticoagulation; providing more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin; Tecarfarin’s metabolism via a single enzyme (CES2) reducing the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events; transforming anticoagulation management for LVAD patients who currently have no alternative options; preventing heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation; addressing the unmet needs in anticoagulation therapy; reducing the clinical complexities of warfarin; and capturing value in a market with high demand for safer, more manageable treatment options. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for LVAD patients who require anticoagulation; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.



View source version on businesswire.com:&nbsp;https://www.businesswire.com/news/home/20250612613022/en/



Corporate and Investor RelationsPaul SaganLaVoieHealthScience(617) 865-0041psagan@lavoiehealthscience.com



MediaAndrew KordaLaVoieHealthScience(617) 865-0043akorda@lavoiehealthscience.com

Release - Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Biotechnology

Cadrenal Therapeutics

CVKD

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Noble Announcement | 2H 2025 Events

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" srcset="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg 300w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1024x876.jpg 1024w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-768x657.jpg 768w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1536x1314.jpg 1536w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-2048x1752.jpg 2048w" sizes="auto, (max-width: 351px) 100vw, 351px" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>